Compare HIMS & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIMS | RGEN |
|---|---|---|
| Founded | 2017 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 8.2B |
| IPO Year | N/A | N/A |
| Metric | HIMS | RGEN |
|---|---|---|
| Price | $19.33 | $143.72 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 11 |
| Target Price | $40.55 | ★ $177.18 |
| AVG Volume (30 Days) | ★ 22.0M | 680.2K |
| Earning Date | 02-23-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.76 | N/A |
| EPS | ★ 0.54 | 0.03 |
| Revenue | ★ $2,210,958,000.00 | $707,890,000.00 |
| Revenue This Year | $62.27 | $17.86 |
| Revenue Next Year | $17.90 | $12.44 |
| P/E Ratio | ★ $42.88 | $5,587.52 |
| Revenue Growth | ★ 78.02 | 11.74 |
| 52 Week Low | $21.12 | $102.97 |
| 52 Week High | $72.98 | $175.77 |
| Indicator | HIMS | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 19.93 | 32.55 |
| Support Level | $28.33 | $138.52 |
| Resistance Level | $27.77 | $160.88 |
| Average True Range (ATR) | 2.34 | 7.17 |
| MACD | -0.72 | -2.22 |
| Stochastic Oscillator | 20.80 | 14.52 |
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.